We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Benign Hematology

Journal Scan / Case Study · January 08, 2020

Resolution of Secondary Hemophagocytic Lymphohistiocytosis After Treatment With the JAK1/2 Inhibitor Ruxolitinib

Blood Advances

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
Resolution of Secondary Hemophagocytic Lymphohistiocytosis After Treatment With the JAK1/2 Inhibitor Ruxolitinib
Blood Adv 2019 Dec 10;3(23)4131-4135, SR Goldsmith, S Saif Ur Rehman, CL Shirai, K Vij, JF DiPersio

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading